


Chemoprevention is not a new concept!



THE AMERICAN JOURNAL OF CANCER

A Continuation of The Journal of Cancer Research

VOLUME XXVII

JUNE, 1936

NUMBER 2

HORMONAL PATHOGENESIS OF ADENOCARCINOMA OF THE
BREAST¹

A. LACASSAGNE¹

(From *L'Institut du Radium, Paris*)

"If one accepts the consideration of adenocarcinoma of the breast as a consequence of a special hereditary sensibility to the proliferative action of œstrone, one is led to imagine a **therapeutic preventive** for subjects predisposed by their heredity to this cancer..."


Conclusions, page 228

Study Of Tamoxifen And Raloxifene (STAR)

P.I. Norman Wolmark MD

Protocol Chairman Victor Vogel MD

Scientific Chairman V. Craig Jordan PhD DSc



**Endometrial Surveillance: Self Reporting
Subproject To Compare Endometrial
And Uterine Characteristics**


B. F. Cain Memorial Lecture

American Association for Cancer Research, 1989

“Important clues have been garnered about the effects of tamoxifen on bone and lipids so it is possible that derivatives could find targeted applications to retard osteoporosis or atherosclerosis. The ubiquitous application of novel compounds to prevent diseases associated with the progressive changes after menopause may, as a side effect, significantly retard the development of breast cancer.”

“The target population would be post-menopausal women in general, thereby avoiding the requirement to select a high risk group to prevent breast cancer.”

Lerner and Jordan, *Cancer Research* 50: 4177-4188, 1990



Jordan, *European Journal of Cancer* 42:2902-2913, 2006



Drug that prevents breast cancer for 20 years: Protection for thousands at high risk

- **New guidelines suggest tamoxifen or raloxifene could offer up to 20 years of protection for those considered at high risk of cancer**
- **Women would take the drugs for five years either before or after the menopause, with the aim of slashing odds of developing the disease**

By [JENNY HOPE](#)

PUBLISHED: 19:00 EST, 14 January 2013 | UPDATED: 05:40 EST, 16 January 2013

[Comments \(115\)](#) | [Share](#)  +1  6 [Tweet](#)  93

Thousands of healthy women could be offered powerful breast cancer drugs to cut their chances of contracting the disease.


New guidelines suggest the drugs tamoxifen or raloxifene could offer as much as 20 years of protection for those considered at high risk of cancer.

The aim is to slash the odds of developing breast cancer in the first place – just as statins are given to patients to stave off heart disease.

ORIGINAL ARTICLE

Lasofoxifene in Postmenopausal Women with Osteoporosis

Steven R. Cummings, M.D., Kristine Ensrud, M.D., Pierre D. Delmas, M.D., Ph.D.,*
Andrea Z. LaCroix, Ph.D., Slobodan Vukicevic, M.D., Ph.D.,
David M. Reid, M.B., Ch.B., M.D., Steven Goldstein, M.D., Ph.D., Usha Sriram, M.D.,
Andy Lee, M.A., John Thompson, Ph.D., Roisin A. Armstrong, Ph.D.,
David D. Thompson, Ph.D., Trevor Powles, M.D., Jose Zanchetta, M.D.,
David Kendler, M.D., Patrick Neven, M.D., Ph.D., and Richard Eastell, M.D.,
for the PEARL Study Investigators†



The Future Promise

- Reduces the risk of fractures
- Reduces the risk of breast cancer
- Reduces the risk of endometrial cancer
- Reduces the risk of coronary heart disease
- Reduces the risk of strokes.

Lasofoxifene- super potent
isomer- SERM



DefinedHealth
unconventional insight

